South Korea’s Ministry of Food and Drug Safety approved Moderna’s updated Spikevax LP.8.1 vaccine targeting the LP.8.1 variant of SARS-CoV-2. This regulatory clearance follows the US FDA’s acceptance of supplemental biologics license applications for two Moderna COVID-19 vaccines, underscoring ongoing efforts to address variant-specific immunization needs. The approval aims to enhance protection amid evolving viral strains and pandemic conditions.